Doravirine/islatravir
 | |
| Combination of | |
|---|---|
| Doravirine | Non-nucleoside reverse transcriptase inhibitor |
| Islatravir | Nucleoside analog reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Idvynso |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a626064 |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Doravirine/islatravir, sold under the brand name Idvynso, is fixed-dose combination medication used for the treatment of HIV/AIDS.[1][2] It contains, doravirine, a HIV-1 non-nucleoside reverse transcriptase inhibitor;[1] and islatravir, a nucleoside analog reverse transcriptase inhibitor.[1] It is taken by mouth.[1]
Medical uses
Doravirine/islatravir is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.[1]
Society and culture
Legal status
The combination doravirine/islatravir was approved for medical use in the United States in April 2026.[3]
Names
The combination doravirine/islatravir is sold under the brand name Idvynso.[3]
References
- 1 2 3 4 5 6 "Idvynso- doravirine, islatravir tablet, film coated". DailyMed. 20 April 2026. Retrieved 5 May 2026.
- ↑ Williams V, Cory TJ (January 2025). "Doravirine/islatravir for the treatment of HIV". Expert Opinion on Pharmacotherapy. 26 (1): 9–15. doi:10.1080/14656566.2024.2440000. PMID 39651697.
- 1 2 "Novel Drug Approvals for 2026". U.S. Food and Drug Administration (FDA). 1 May 2026. Retrieved 5 May 2026.
This article incorporates text from this source, which is in the public domain.
External links
- Clinical trial number NCT05631093 for "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)" at ClinicalTrials.gov
- Clinical trial number NCT05630755 for "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)" at ClinicalTrials.gov